

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION (RCE)

Subsection (b) of 35 U.S.C. §132, effective on May 29, 2000, provides for continued examination of a utility or plant application filed on or after Jun 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/401,636
Filing Date	September 22, 1999
First Named Inventor	Lars Hellman
Group Art Unit	1644
Examiner Name	Margaret E. Jamroz
Attorney Docket Number	10223-006001

This is a Request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above-identified application.

NOTE: 37 C.F.R. §1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. §1.114

- a. ☐ Previously submitted
- ☐ Consider the amendment(s)/reply under 37 C.F.R. §1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered)
 - ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
 - ☐ Other _____
- b. ☒ Enclosed
- ☒ Amendment/Reply (9 pages)
 - ☐ Affidavit(s)/Declaration(s)
 - ☐ Information Disclosure Statement (IDS)
 - ☒ Other Transmittal of Formal Drawings (10 drawings)

COPY OF PAPERS
ORIGINALLY FILED

04/16/2002 6TEFFERA 0000003 09/401636

01 FC:279

370.00 00

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. §1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; fee under 37 C.F.R. §1.17(i) required)
- b. ☐ Other _____

3. Fee The RCE fee under 37 C.F.R. §1.17(e) is required by 37 C.F.R. §1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 06-1050
- ☒ RCE fee required under 37 C.F.R. §1.17(e)
 - ☒ Extension (one month) of time fee (37 C.F.R. §§1.136 and 1.17)
 - ☐ Other _____
- b. ☒ Checks in the amount of \$ 370 & \$55 enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)


SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED

Name (Print/Type)	Anton J. Bokal IV	Registration No. (Attorney/Agent)	51,243
Signature	<i>Anton J. Bokal IV</i>	Date	April 4, 2002

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to **Commissioner for Patents, Box RCE, Washington, DC 20231** or facsimile transmitted to the U.S. Patent and Trademark Office on: April 4, 2002

Name (Print/Type)	Kathryn J. Sanderson	Date	April 4, 2002
Signature	<i>Kathryn J. Sanderson</i>		



Attorney's Docket No.: 10223-006001

23/F
ES/4/24/02
RECEIVED
APR 19 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lars Hellman
Serial No. : 09/401,636
Filed : September 22, 1999
Title : IMMUNOGENIC POLYPEPTIDES FOR INDUCING ANTI-SELF IGE RESPONSES

Art Unit : 1644
Examiner : Margaret E. Jamroz

Box RCE
Commissioner for Patents
Washington, DC 20231

COPY OF PAPERS
ORIGINALLY FILED

AMENDMENT

In response to the Final Office Action mailed December 4, 2001 (Paper No. 18, hereafter referred to as "OA"), please amend the application as follows:

In the specification:

Please amend the title to read as follows:

-- IMMUNOGENIC POLYPEPTIDES FOR INDUCING ANTI-SELF IgE
RESPONSES --

In the claims:

Please cancel claims 1, 2, and 4-11.

Please amend claim 25, 27, 30-33, 35, 38-41, 45-48, 50, and 52-54 as follows:

25. (Amended once) An immunogenic polypeptide, comprising a self IgE CH3 domain and one or more non-self IgE domains, wherein said immunogenic polypeptide is effective to induce

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit April 4, 2002
Signature Kathryn J. Sanderson

Kathryn J. Sanderson
Typed or Printed Name of Person Signing Certificate